Review Papers Claim by Claim

Visual summary — convergent signatures: Ageing ≈ Injury; DR reverses

1) What the paper shows (evidence-backed bullets)

• Paired RNA-seq and DIA proteomics on the same sciatic nerves across ages (Y=3mo, O=20mo, G=24mo) and lifelong DR (n=6 per ageing group) revealing module-level co-expression changes (WGCNA/CEMiTool) that segregate into inflammatory, metabolic and developmental clusters Methods and co-expression modules
• Proteomic time-course after sciatic nerve crush (3,7,28 dpc) shows an interferon/Stat1-dominated response early (3–7d) that resolves by 28dpc; the same Stat1/ISG cluster (Mostafavi et al. network C3) is induced in geriatric intact nerves and prevented by DR Stat1/ISG induction in ageing and injury
• Ageing-associated modules are enriched for interferon, NF-κB, phagocytosis and phagolysosomal GO terms; cell-type ORA implicates macrophages and Schwann cells, consistent with inflammageing and Schwann cell repair-like states Functional enrichment & cell-type ORA
• DR upregulates metabolic pathways (glycolysis, oxidative phosphorylation, AMPK signaling, BCAA degradation) and preserves axonal/myelin proteins while preventing phagolysosomal upregulation seen in geriatric AL nerves — suggesting DR induces a late-regeneration-like metabolic program that is protective DR metabolic signature and myelin preservation

2) Strengths

1. Deep multi-omics from the same tissue (paired transcriptome + proteome) across ages with an intervention (DR) and independent injury time course — increases biological interpretability and cross-validation at mRNA and protein levels Data depth and deposition
2. Clear statistical pipeline: DESeq2/apeglm for RNA, Spectronaut directDIA + FDR controls for proteomics, WGCNA/CEMiTool for modules, ORA/GSEA and TF motif analyses — methods are well-established and transparent with code/data links in supplement and repositories.
3. Biologically plausible cross-validation: interferon/Stat1 induction after nerve injury is reported elsewhere (cGAS/STING literature) and matches the temporal pattern seen here (early increase, late decline) cGAS/STING->IFN in nerve injury

3) Key limitations, blindspots and alternative explanations

• Species & translation: Data are from mouse sciatic nerve; generalization to human PNS ageing or idiopathic neuropathy needs validation (human datasets show inflammatory signatures in DPN/CIDP but with different cell composition and clinical contexts) Human DPN — inflammatory remodeling
• Bulk tissue resolution: Bulk RNA/protein mixes neuronal, Schwann, vascular and immune signals. ORA using external scRNA markers helps but cannot assign causality or single-cell specificity; single-cell/single-nucleus profiling from matched aged nerves would strengthen cell-resolved claims (authors re-used Zhao et al. iSNAT data for validation but that is from injury atlas) iSNAT single-cell resource
• Causality vs correlation: Observed DR-associated prevention of Stat1/ISG induction is correlative. Whether DR acts directly on nerve-resident cells (Schwann cells, macrophages) or systemically (metabolic/hormonal) is not proven by these data; interventional perturbation (e.g., Stat1 knockout restricted to Schwann cells/macrophages or DR mimetics) would be decisive.
• Sex & DR regimen: The methods note DR implemented in female mice (per Extended Data); sex-specific effects are plausible and not fully resolved — many DR effects are sex-biased. This limits generalizability unless both sexes are tested or sex analyzed explicitly.
• Proteome coverage & dynamic range: DIA proteomics is robust, but low-abundance cytokines/secreted mediators or post-translational modifications (phosphorylation of STATs) might be missed; the inference that Stat1 is active relies on protein abundance of STAT1 and ISGs but not phospho-STAT1 measurements or cell-type–resolved activation assays.
• Inflammation source ambiguity: Increased ISGs and macrophage markers may reflect either resident macrophage activation or peripheral immune cell infiltration; the paper's ORA implicates macrophage markers but lacks orthogonal cell quantification (immunostaining/flow cytometry) in the ageing cohorts to confirm infiltration magnitude and origin.

4) How robust is the 'old nerve = injured nerve' conclusion?

The data make a strong case that old (24mo) murine sciatic nerves show proteomic profiles overlapping with early post-injury stages (3–7 dpc): interferon/ISG induction, phagolysosomal upregulation and loss of axonal/myelin proteins. Correlation networks and shared enriched GO/KEGG terms substantiate convergence. However, key caveats remain:

1. Shared signatures do not prove identical cellular/functional states: acute injury triggers coordinated degeneration/regeneration programs (clear cell death, myelin debris, active phagocytosis) that may be only partially mirrored by chronic low-grade inflammatory remodeling in ageing; temporal dynamics and resolution differ (injury resolves by 28dpc; geriatric nerve remains chronically altered).
2. Functional readouts are limited: the paper cites prior physiology (NCV decline ~20mo) and structural studies; this study itself reports molecular overlap but not parallel functional assays (e.g., phagocytosis assays, in vivo macrophage depletion during ageing) inside the same cohorts, except referencing Yuan et al. macrophage depletion improving aged nerve structure Macrophage depletion improves aged nerve

5) Reproducibility and data availability

Excellent: RNA-seq deposited at GEO (GSE137504, GSE318229); proteomics at MassIVE (MSV000100637, MSV000100636) and PRIDE (PXD041026) for injury datasets; methods, parameters and R packages are enumerated in methods allowing reanalysis. This yields high reproducibility potential, subject to independent replication in other labs and in both sexes Data deposition and methods transparency

6) Specific, testable follow-ups (experiments that would falsify or confirm key claims)

1. Cell-type conditional STAT1 loss-of-function: delete Stat1 in Schwann cells (P0-Cre/Stat1fl/fl) or myeloid cells (Cx3cr1-CreERT2/Stat1fl/fl) and measure whether aged nerves still acquire injury-like ISG signatures and whether regenerative deficits are altered; if STAT1 deletion prevents the aged injury-like proteome and restores function, causal role strengthened.
2. Single-nucleus or single-cell multiome (snRNA+ATAC or snRNA+proteome) of aged intact sciatic nerve to resolve whether Schwann cells adopt an 'injury-like' repair state transcriptionally and epigenetically, and to map which cell types express ISGs in ageing vs injury.
3. DR mimetic intervention in aged mice (e.g., acutely starting rapamycin/metformin/AMPK agonists) to test whether short-term metabolic modulation reverses the Stat1/ISG and phagolysosomal signatures — would separate lifelong developmental effects from reversible metabolic signaling.
4. Quantitative histology/flow cytometry on matched cohorts to measure macrophage abundance, myelin debris, and Schwann cell repair markers to corroborate bulk-omics in cellular terms.

7) Immediate practical takeaways for researchers

• Use the deposited datasets (GEO / MassIVE / PRIDE) to re-test cell-specific hypotheses (e.g., cross-map proteome hits to scRNA markers) — authors provide mapping guidance and supplementary datasets.
• When modeling PNS ageing, measure interferon/Stat1 activity (both protein abundance and phosphorylation) as a candidate biomarker of injury-like ageing states.
• Consider dietary/metabolic interventions as potential modulators of inflammageing in peripheral nerves; test short-term DR-mimetic treatments in aged cohorts to evaluate reversibility.

8) Short critical summary sentence

Robust multi-omic evidence supports that aged mouse peripheral nerve adopts an injury-like inflammatory and metabolic program (Stat1/ISG prominent) that lifelong dietary restriction can dampen; causality, cell-specific sources, sex differences and human translation remain open and important next steps Study.